# OncoDNA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncodna

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.oncodna.com
- Total disclosed funding: $19M
- Latest round: Series C (Jun 22, 2023)
- Investors on record: 11

## About

Founded in 2012 by François Blondel, and Jean-Pol Detiffe, and based in Gosselies, Belgium, OncoDNA SA is a medical diagnostic company that develops precision medicines for the treatment of cancer and other genetic diseases. In July 2023, OncoDNA SA raised EUR 6.5 million in series C funding from Ackermans & van Haaren, CPH, Sambrinvest, SFPI-FPIM, Société Régionale d'Investissement de Wallonie, Swisscanto Invest by Zürcher Kantonalbank, and Vesalius Biocapital. As of May 2023, the firm is being led by its CEO, Bernard Courtieu. 

The firm’s services include translational research, drug development, patient testing and treatment, monitoring, and reimbursement through collaborations and partnerships with various healthcare providers and institutions. The company explores and interprets genetic data collected of patients to deliver precision medicine to treat cancer and other genetic diseases in humans.

## Funding rounds

- Series C, Jun 22, 2023, $7.3M — Ackermans & van Haaren, Société Régionale d'Investissement de Wallonie, Vesalius Biocapital, SFPI-FPIM, Sambrinvest, Verve Ventures, IPG-BIO.be, CPH, Swisscanto
- Series B, Apr 3, 2020, $12M — Ackermans & van Haaren, Société Régionale d'Investissement de Wallonie, Vesalius Biocapital, SFPI-FPIM, Sambrinvest, CPH, Inventures, Swisscanto, Verve Ventures, Future Capital AG Hessen Life Sciences Chemie

## Investors

- Ackermans & van Haaren (https://capitalatlas.ai/funds/ackermans-van-haaren) — Series B, Series C
- Société Régionale d'Investissement de Wallonie — Series B, Series C
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series B, Series C
- SFPI-FPIM — Series B, Series C
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series B, Series C
- CPH — Series B, Series C
- Inventures (https://capitalatlas.ai/funds/inventures) — Series B
- Swisscanto (https://capitalatlas.ai/funds/swisscanto) — Series B, Series C
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Series B, Series C
- Future Capital AG Hessen Life Sciences Chemie — Series B
- IPG-BIO.be — Series C